摘要
目的观察参附注射液对慢性阻塞性肺疾病急性加重(AECOPD)患者细胞免疫功能指标的影响,并对其安全性进行评价。方法纳入符合受试条件的AECOPD住院患者70例,采用随机数字表法将其随机分成两组。对照组仅予以西医常规治疗,治疗组在西医常规治疗的基础上合用参附注射液。两组治疗14 d,随访3个月,记录两组治疗前、治疗7 d以及治疗14 d后的各项症状体征积分、细胞免疫指标,记录两组治疗前、治疗1个月后的肺功能指标,记录两组治疗3个月后的再住院情况,并观察两组在治疗过程中出现的不良反应。采用SPSS21.0统计软件进行统计处理,评价其临床疗效和安全性。结果 1)两组在治疗前基线比较,均衡一致(P>0.05)。2)治疗14 d后,治疗组总有效率为91.18%,对照组总有效率为80.56%,治疗组优于对照组(P<0.01)。3)两组能明显提高患者Th、Th/Ts、B淋巴细胞,降低Ts等指标(P<0.01),而总T淋巴细胞较治疗前无明显变化(P>0.05);治疗组在改善Th、Ts、Th/Ts、B淋巴细胞等方面优于对照组(P<0.05)。4)治疗1月后两组能明显提高患者的FEV1%预计值(P<0.01);治疗后治疗组能提高患者的FEV1/FVC(P<0.05),对照组FEV1/FVC与治疗前比较无明显改善(P>0.05);治疗组改善患者FEV1%预计值、FEV1/FVC优于对照组(P<0.05)。5)两组比较,3个月内再住院率疗效相当(P>0.05)。6)两组均未发生严重的不良情况。结论AECOPD患者存在免疫功能紊乱,参附注射液能改善AECOPD患者的细胞免疫功能,提高机体的抗病能力,减少患者的住院频率,提高患者的生活生存质量,且无不良事件发生。
Objective： To observe the effect of Shenfu Injection on cellular immune function in patients with AECOPD,and to assess its safety. Methods： 70 inpatients with AECOPD were randomly divided into the treatment group and the control group. The control group only received standard Western medicine therapy,while the treatment group received additional Shenfu Injection. Both groups were treated for 14 days and followed up for 3 months. The symptom scores and cellular immune indexes were recorded before treatment,7 days and 14 days after treatment,respectively,as well as lung function before treatment and one month after treatment,and re-admission 3 months after treatment,and adverse reactions were observed in two groups during treatment. SPSS21.0 statistical software was used for statistical analysis to evaluate its clinical efficacy and safety. Results： 1）The two groups had the same equilibrium and comparability at baseline before treatment（P〉0.05）. 2）After 14 days of treatment,the total effective rate of the treatment group was 91.18%,and that of the control group was 80.56%.The treatment group was superior to the control group（P〈0.01）. 3）Th,Th/Ts,and B lymphocytes were significantly increased,while the Ts index were decreased in both groups（P〈0.01）. However,the total T lymphocytes were not obviously changed after treatment（P〉0.05）. The treatment group was superior to the control group in improving Th,Ts,Th/Ts and B lymphocytes（P〈0.05）. 4）After 1 month of treatment,the FEV1% were significantly increased in the two groups（P〈0.01）. After treatment,The FEV1/FVC were improved in the treatment group（P〈0.05）,while there was no significant improvement in the control group（P〉0.05）. The treatment group was superior to the control group in improving FEV1% prediction value and FEV1/FVC（P〈0.05）. 5）The re-admission rate was similar between the two groups in 3 months（P〉0.05）. 6）There was no serious adverse reaction in both groups. Conclusion： Shenfu Inj
作者
金伟
宋洋
罗晓琼
李艳青
李宜为
张颖
Jin Wei;Song Yang;Luo Xiaoqiong(Affiliated Hospital of Chengdu University of Traditional Chinese Medicine ,Sichunn , Chengdu 610072, China)
出处
《中国中医急症》
2018年第7期1182-1185,共4页
Journal of Emergency in Traditional Chinese Medicine
基金
北京协和医学基金会睿E(睿意)急诊医学研究专项基金(H2016061)
关键词
慢性阻塞性肺疾病急性加重
参附注射液
细胞免疫功能
Acute exacerbation of chronic obstructive pulmonary disease
Shenfu Injection
Cellular immune function
